Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Pediatric Nephrology
Erschienen in: Pediatric Nephrology 3/2006

01.03.2006 | Review

The use of levo-carnitine in children with renal disease: a review and a call for future studies

verfasst von: Brook Belay, Nora Esteban-Cruciani, Christine A. Walsh, Frederick J. Kaskel

Erschienen in: Pediatric Nephrology | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

Carnitine is an amino acid derivative that has a key role in the regulation of fatty acid metabolism and ATP formation. Carnitine deficiency has been described in various conditions, including chronic kidney disease (CKD) and end stage renal disease (ESRD). The deficiency of this micronutrient is postulated to lead to adverse effects across multiple organ systems. There is a paucity of information on carnitine deficiency and its effects in the pediatric CKD and ESRD populations. Currently, there is no evidence supporting the routine use of carnitine supplementation in children with ESRD. In this article, we review the pathophysiology, pharmacokinetics and the potential effects of levo-carnitine supplementation with a focus on the pediatric CKD and ESRD populations. Finally, potential future directions of research are discussed.
Literatur
1.
Matera M, Bellinghieri G, Constantino G, Santoro D, Calavani M, Savica V (2003) History of L-carnitine: implications for renal disease. J Renal Nutr 13:2–14CrossRef
2.
Bremer J (1983) Carnitine—metabolism and functions. Physiol Rev 63:1420–1480PubMed
3.
Fraenkel G, Friedman S (1957) Carnitine. Harris RS, Marrian GF, Thimann DV (eds) Vitamins and hormones. Academic, New York, pp 73–118
4.
Kaneko T, Yoshida R (1962) On the absolute configuration of L-carnitine. Bull Chem Soc Jpn 35:1153–1155
5.
Labadie J, Dunn WA, Aronson NN Jr. (1976) Hepatic synthesis of carnitine from protein-bound trimethyllysine. Biochem J 160:85–96PubMed
6.
Colquhoun A (1998) Induction of apoptosis by polyunsaturated fatty acids and its relationship to fatty acid inhibition of carnitine palmitoyltransferase I activity in Hep2 cells. Biochem Mol Biol Int 45:331–336PubMed
7.
Brass EP, Beyerinck RA (1988) Effects of propionate and carnitine on the hepatic oxidation of short- and medium-chain-length fatty acids. Biochem J 250:819–825PubMed
8.
Mister M, Noris M, Szymczuk J, Azzollini N, Aiello S, Abbate M, Trochimowicz L, Gagliardini E, Arduini A, Perico N, Remuzzi G (2002) Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. Kidney Int 61:1064–1078CrossRefPubMed
9.
Loster H, Keller T, Grommisch J, Grunder W (1999) Effects of L-carnitine and its acetyl and propionyl esters on ATP and PCr levels of isolated rat hearts perfused without fatty acids and investigated by means of 31P-NMR spectroscopy. Mol Cell Biochem 200:93–102CrossRefPubMed
10.
Rebouche CJ, Engel AG (1983) Kinetic compartmental analysis of carnitine metabolism in the dog. Arch Biochem Biophys 220:60–70CrossRefPubMed
11.
Friolet R, Hoppeler H, Krahenbuhl S (1994) Relationship between the coenzyme A and the carnitine pools in human skeletal muscle at rest and after exhaustive exercise under normoxic and acutely hypoxic conditions. J Clin Invest 94:1490–1495PubMed
12.
DiMauro S, DiMauro PM (1973) Muscle carnitine palmityltransferase deficiency and myoglobinuria. Science 182:929–931PubMed
13.
Bank WJ, DiMauro S, Bonilla E, Capuzzi DM, Rowland LP (1975) A disorder of muscle lipid metabolism and myoglobinuria. Absence of carnitine palmitoyl transferase. N Engl J Med 292:443–449PubMed
14.
Winter SC, Buist NR (2000) Cardiomyopathy in childhood, mitochondrial dysfunction, and the role of L-carnitine. Am Heart J [Suppl] 139:S63–S69
15.
Iacobazzi V, Pasquali M, Singh R, Matern D, Rinaldo P, Amat di San Filippo C, Palmieri F, Longo N (2004) Response to therapy in carnitine/acylcarnitine translocase (CACT) deficiency due to a novel missense mutation. Am J Med Genet A 126:150–155CrossRefPubMed
16.
Pierpont ME, Breningstall GN, Stanley CA, Singh A (2000) Familial carnitine transporter defect: A treatable cause of cardiomyopathy in children. Am Heart J 139:S96–S106CrossRefPubMed
17.
Petrykowski WV, Ketelsen WP, Schmidt-Sommerfeld E, Penn D, Sawicka E, Struck E, Lehnert W, Haap K, Strassburg HM (1985) Primary systemic carnitine deficiency under successful therapy: clinical, biochemical, ultrahistochemical and renal clearance studies. Clin Neuropath 4:63–71
18.
Scholte HR, Rodrigues Pereira R, de Jonge PC, Luyt-Houwen IE, Hedwig M, Verduin M, Ross JD (1990) Primary carnitine deficiency. J Clin Chem Clin Biochem 28:351–357PubMed
19.
Helton E, Darragh R, Francis P, Fricker FJ, Jue K, Koch G, Mair D, Pierpont ME, Prochazka JV, Linn LS, Winter SC (2000) Metabolic aspects of myocardial disease and a role for L-carnitine in the treatment of childhood cardiomyopathy. Pediatrics 105:1260–1270PubMed
20.
Tein I (2002) Role of carnitine and fatty acid oxidation and its defects in infantile epilepsy. J Child Neurol [Suppl] 17: S57–S82
21.
Winter SC, Szabo-Aczel S, Curry CJ, Hutchinson HT, Hogue R, Shug A (1987) Plasma carnitine deficiency. Clinical observations in 51 pediatric patients. Am J Dis Child 141:660–665PubMed
22.
Kurtin PS (1990) Carnitine metabolism and usage in chronic dialysis patients. Semin Dial 3:166–170
23.
Savica V, Bellinghieri G, Di Stefano C, Corvaja E, Consolo F, Corsi M, Maccari F, Spagnoli LG, Villaschi S, Palmieri G (1983) Plasma and muscle carnitine levels in hemodialysis patients with morphological-ultrastructural examination of muscle samples. Nephron 34:232–236
24.
Moorthy AV, Rosenblum M, Rajaram R, Shug AL (1983) A comparison of plasma and muscle carnitine levels in patients on peritoneal or hemodialysis for chronic renal failure. Am J Nephrol 3:205–208PubMed
25.
Hoppel C (2003) The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis 41 [Suppl 4]:S4–S12
26.
Smogorzewski M, Perna AF, Borum PR, Massry SG (1988) Fatty acid oxidation in the myocardium: effects of parathyroid hormone and CRF. Kidney Int 34:797–803PubMed
27.
Schmidt-Sommerfeld E, Werner D, Penn D (1988) Carnitine plasma concentrations in 353 metabolically healthy children. Eur J Pediatr 147:356–360CrossRefPubMed
28.
Deufel T (1990) Determination of L-carnitine in biological fluids and tissues. J Clin Chem Clin Biochem 28:307–311PubMed
29.
Barns RJ, Bowling FG, Brown G, Clague AE, Thompson A (1991) Carnitine in dried blood spots: a method suitable for neonatal screening. Clinica Chimica Acta 197:27–34CrossRef
30.
Chace DH, Pons R, Chiriboga CA, McMahon DJ, Tein I, Naylor EW, De Vivo D (2003) Neonatal blood carnitine concentrations: normative data by electrospray tandem mass spectrometry. Pediatr Res 53:823–829CrossRef
31.
Gloggler A, Bulla M, Puchstein C, Gulotta F (1988) Plasma and muscle carnitine in healthy and hemodialyzed children. Child Nephrol Urol 9:277–282PubMed
32.
Chalmers RA, Roe CR, Stacey TE, Hoppel CL (1984) Urinary excretion of l-carnitine and acylcarnitines by patients with disorders of organic acid metabolism: evidence for secondary insufficiency of l-carnitine. Pediatr Res 18:1325–1328PubMed
33.
Mamoulakis D, Galanakis E, Dionyssopoulou E, Evangeliou A, Sbyrakis S (2004) Carnitine deficiency in children and adolescents with type 1 diabetes. J Diabetes Complications 18:271–274CrossRefPubMed
34.
Brass EP (1995) Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients. Clin Ther 17:176–185CrossRefPubMed
35.
Rebouche CJ, Engel AG (1984) Kinetic compartmental analysis of carnitine metabolism in the human carnitine deficiency syndromes. J Clin Invest 73:857–867PubMed
36.
Evans AM, Faull R, Fornasini G, Lemanowics EF, Longo A, Pace S, Nation RL (2000) Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis. Clin Pharmacol Ther 68:238–249CrossRefPubMed
37.
Gusmano R, Oleggini R, Perfumo F (1981) Plasma carnitine concentrations and dyslipidemia in children on maintenance hemodialysis. J Pediatr 3:429–432
38.
Bartel LL, Hussey JL, Shrago E (1982) Effect of dialysis on serum carnitine, free fatty acids, and triglyceride levels in man and the rat. Metabolism 31:944–947CrossRefPubMed
39.
Debska-Slizien A, Kawecka A, Wofnarowski K, Prajs J, Malgorzewicz S, Kunicka D, Zdrojewski Z, Lysiak-Szydlowska W, Lipinski J, Rutkowski (2000) Correlation between plasma carnitine, muscle carnitine and glycogen levels in maintenance hemodialysis patients. Int J Artif Organs 23:90–96PubMed
40.
Vacha GM, Corsi M, Giorcelli G, D’Iddio S, Maccari F (1985) Serum and muscle L-carnitine levels in hemodialyzed patients during and after long-term L-carnitine treatment. Curr Ther Res 37:505–516
41.
Bellinghieri G, Savica V, Mallamace A (1983) Correlation between increased serum and tissue L-carnitine levels and improved muscle symptoms in hemodialyzed patients. Am J Clin Nutr 38:523–531PubMed
42.
Evans A (2003) Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis 41 [Suppl 4]:S13–S26
43.
Bernardini I, Rizzo WB, Dalakas M, Bernar J, Gahl WA (1985) Plasma and muscle free carnitine deficiency due to renal Fanconi syndrome. J Clin Invest 75:1124–1130PubMed
44.
Gahl WA, Bernardini I, Dalakas M, Rizzo WB, Harper GS, Hoeg JM, Hurko O, Bernar J (1988) Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest 81:549–560PubMed
45.
Gahl WA, Bernardini IM, Dalakas MC, Markello TC, Krasnewich DM, Charnas LR (1993) Muscle carnitine repletion by long-term carnitine supplementation in nephropathic cystinosis. Pediatr Res 34:115–119PubMed
46.
Asami T, Yanagihara T, Tomisawa S, Hayakawa H, Uchiyama M (1996) Serum carnitine concentrations in different glomerular diseases with normal renal function. Nippon Jinzo Gakkai Shi 38:229–232PubMed
47.
Labonia WD, Morelli OH Jr, Gimenez MI, Freuler PV, Morelli OH (1987) Effects of L-carnitine on sodium transport in erythrocytes from dialyzed uremic patients. Kidney Int 32:754–759PubMed
48.
Donatelli M, Terrizzi C, Zumro G, Russo V, Bucalo M, Scarpinaro A (1987) Effects of L-carnitine on chronic anemia and adenosine triphosphate concentration in hemodialyzed patients. Curr Ther Res 41:620–624
49.
Arduini A, Rossi M, Mancinelli G, Belfiglio M, Scurti R, Radatti G, Shohet SB (1990) Effect of L-carnitine and acetyl-L-carnitine on the human erythrocyte membrane stability and deformability. Life Sci 47:2395–2400CrossRefPubMed
50.
Galluci MT, Lubrano R, Meloni C, Morosetti M, Manca di Villahermosa S, Scoppi P, Palombo G, Castello MA, Casciani CU (1999) Red blood cell membrane lipid peroxidation and resistance to erythropoietin in hemodialysis patients. Clin Nephrol 52:239–245PubMed
51.
Golper TA, Goral S, Becker BN, Langman CB (2003) L-carnitine treatment of anemia. Am J Kidney Dis 41 [Suppl 4]:S27–S34
52.
Hurot JM, Cucherat M, Haugh M, Fouque D (2002) Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 13:708–714PubMed
53.
Eknoyan G, Latos DL, Lindberg J (2003) Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National kidney foundation. Carnitine consensus conference. Am J Kidney Dis 41:868–876CrossRefPubMed
54.
Lilien MR, Duran M, Quak JM, Frankhuisen JJ, Schroder CH (2000) Oral L-carnitine does not decrease erythropoietin requirement in pediatric dialysis. Pediatr Nephrol 15:17–20CrossRefPubMed
55.
Berard E, Iordache A (1992) Effect of low doses of L-carnitine on the response to recombinant human erythropoietin in hemodialyzed children: about two cases. Nephron 62:368–369PubMed
56.
Schroder CH, European Pediatric Peritoneal Dialysis Working Group (2003) The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee. Pediatr Nephrol 18:805–809CrossRefPubMed
57.
Siliprandi N, Di Lisa F, Menabo R (1990) Clinical use of carnitine. Past, present and future. Adv Exp Med Biol 272:175–181PubMed
58.
Lacour B, Di Giulio S, Chanard J, Ciancioni C, Haguet M, Lebkiri B, Basile C, Drueke T, Assan R, Funch-Brentano JL (1980) Carnitine improves lipid anomalies in haemodialysis patients. Lancet 2:763–764CrossRefPubMed
59.
Bohles H, Michalk D, von Wendt-Goknur E (1991) Effect of L-carnitine supplementation on lipid metabolism of renal failure, dialysis-dependent children and adolescents. Infusionstherapie 18:224–226PubMed
60.
Wanner C, Forstner-Wanner S, Shaeffer G, Schollmeyer P, Horl WH (1986) Serum free carnitine, carnitine esters and lipids in patients on peritoneal dialysis and hemodialysis. Am J Nephrol: 206–211
61.
Grzegozewska AE, Mariak I, Dobrowolska-Zachwieja A (1999) Continuous ambulatory peritoneal dialysis (CAPD) adequacy influences serum free carnitine level. Int Urol Nephrol 31:533–540CrossRefPubMed
62.
Constantin-Teodosiu D, Kirby DP, Short AH, Burden RP, Morgan AG, Greenhaff PL (1996) Free and esterified carnitine in continuous ambulatory peritoneal dialysis patients. Kidney Int 49:158–162PubMed
63.
Zilleruelo G, Freundlich M, Novak M, Frodada J, Abitbol C, Montane B, Strauss J (1984) Carnitine losses in children on hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD). Pediatr Res 18:373A
64.
Zilleruelo G, Freundlich M, Novak M, Frodada J, Abitbol C, Montane B, Strauss J (1985) Favorable effect of L-carnitine supplementation during hemodialysis. Pediatr Res 19:386A
65.
Bacri JL, Lacour B, Tete MJ, Broyer M (1981) Effects of L-carnitine in hemodiaylzed pediatric patients. Kidney Int 20:426
66.
Zilleruelo G, Novak M, Hsia SL, Goldberg R, Abitbol C, Monkus E, Strauss J (1989) Effect of dialysate composition on the lipid response to L-carnitine supplementation. Kidney Int 36 [Suppl 27]:S259–S263
67.
Gloggler A, Bulla M, Furst P (1989) Effect of low dose supplementation of L-carnitine on lipid metabolism in hemodialyzed children. Kidney Int 36 [Suppl 27]:S256–S258
68.
Warady BA, Borum P, Stall C, Millspaugh J, Taggart E, Lum G (1990) Carnitine status of pediatric patients on continuous ambulatory peritoneal dialysis. Am J Nephrol 10:109–114PubMed
69.
Murakami R, Momota T, Yoshiya K, Yoshikawa N, Nakamura H, Honda M, Ito H (1990) Serum carnitine and nutritional status in children treated with continuous ambulatory peritoneal dialysis. J Pediatr Gastronenterol Nutr 11:371–374
70.
Zachwieja J, Duran M, Joles JA, van de Hurk D, Frankhuisen JJ, Donckerwolcke RAMG (1994) Amino acid and carnitine supplementation in haemodialyzed children. Pediatr Nephrol 8:739–743CrossRefPubMed
71.
Kosan C, Sever L, Ansoy N, Caliskan S, Kasapcopur O (2003) Carnitine supplementation improves apolipoprotein B levels in pediatric peritoneal dialysis patients. Pediatr Nephrol 18:1184–1188CrossRefPubMed
72.
Fritz IB, Arrigoni-Martelli E (1993) Sites of action of carnitine and its derivatives on the cardiovascular system: interactions with membranes. Trends Pharmacol Sci 14:355–360CrossRefPubMed
73.
Sakurabayashi T, Takaesu Y, Haginoshita S, Takeda I, Aoike I, Miyazaki S, Koda Y, Yuasa Y, Sakai S, Suzuki M, Takahashi S, Hirasawa Y, Nakamura T (1999) Improvement of myocardial fatty acid metabolism through L-carnitine administration to chronic hemodialysis patients. Am J Nephrol 19:480–484CrossRefPubMed
74.
Matsumoto Y, Motoyoshi S, Ohashi H, Araki H, Tadokoro, Osumi Y, Ito H, Morita H, Amano I (2000) Effects of L-carnitine supplementation on cardiac morbidity in hemodialyzed patients. Am J Nephrol 20:201–207CrossRefPubMed
75.
Fagher B, Cederblad G, Monti M, Olsson L, Rasmusen B, Thysell H (1985) Carnitine and left ventricular function in haemodialysis patients. Scand J Clin Lab Invest 45:193–198PubMed
76.
Ahmad S, Robertson HT, Golper TA, Wolfson M, Kurtin P, Katz LA, Hirschberg R, Nicora R, Ashbrook DW, Kopple JD (1990) Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int 38:912–918PubMed
77.
Brass EP, Adler S, Sietsema KE, Hiatt WR, Orlando AM, Amato A (2001) Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis 37:1018–1028PubMed
78.
Topaloglu R, Celiker A, Saatci U, Kilinc K, Bakkaloglu A, Besbas N, Tokel S, Tokel K (1998) Effect of carnitine supplementation on cardiac function in hemodialyzed children. Acta Paediatr Jpn 40:26–29PubMed
79.
Khoss AE, Steger H, Legenstein E, Proll E, Salzer-Muhar U, Schlemmer M, Balzar E, Wimmer M (1989) L-carnitine therapy and myocardial function in children treated with chronic hemodialysis. Wien Klin Wochenschr 101:17–20PubMed
80.
Steinman TI, Nissenson AR, Glassock RJ, Dickmeyer J, Mattern WD, Parker TF 3rd, Hull AR (2003) L-carnitine use in dialysis patients: is national coverage for supplementation justified? What were CMS regulators thinking—or were they? Nephrol News Issues 17:28–36
Metadaten
Titel
The use of levo-carnitine in children with renal disease: a review and a call for future studies
verfasst von
Brook Belay
Nora Esteban-Cruciani
Christine A. Walsh
Frederick J. Kaskel
Publikationsdatum
01.03.2006
Verlag
Springer-Verlag
Erschienen in
Pediatric Nephrology / Ausgabe 3/2006
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-005-2085-4

Weitere Artikel der Ausgabe 3/2006

Pediatric Nephrology 3/2006 Zur Ausgabe

Letter to the Editors

Childhood membranous nephropathy in association with interstitial nephritis and Fanconi syndrome

Original Article

Glomerular expression of transforming growth factor–β (TGF-β) isoforms in mice lacking CD2-associated protein

Brief Report

Clinical and molecular findings in a family with the carbonic anhydrase II deficiency syndrome

Clinical Quiz

A patient with hematuria and cystic renal mass: Answer

Brief Report

Severe renovascular hypertension in an infant with congenital solitary pelvic kidney

Book Review

C. Ronco, R. Bellomo, A. Brendolan (eds): Sepsis, kidney and multiple organ dysfunction (Contributions to Nephrology series, vol 144) and R.M. Lindsay (ed); U. Buoncristiani, R.S. Lockridge, A. Pierratos, G.O. Ting (co-eds): Daily and nocturnal hemodialysis (Contributions to Nephrology series, vol 145)

Neu im Fachgebiet Pädiatrie

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise